A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency (Part B)
Latest Information Update: 24 Feb 2026
At a glance
- Drugs SR 604 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; First in man
- Sponsors Equilibra Bioscience
Most Recent Events
- 17 Feb 2026 Planned End Date changed from 27 Apr 2026 to 1 Jul 2026.
- 17 Feb 2026 Planned primary completion date changed from 27 Apr 2026 to 1 Jul 2026.
- 09 Oct 2025 The protocol has been amended that in this study only male subjects can participate.